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Epstein-Barr virus (EBV) infection of primary B cells causes B-cell activation and proliferation. Activation
of B cells requires binding of antigen to the B-cell receptor and a survival signal from ligand-bound CD40,
signals that are provided by the EBV LMP1 and LMP2A latency proteins. Recently, Toll-like receptor (TLR)
signaling has been reported to provide a third B-cell activation stimulus. The interaction between the EBV and
TLR pathways was therefore investigated. Both UV-inactivated and untreated EBV upregulated the expression
of TLR7 and downregulated the expression of TLR9 in naive B cells. UV-inactivated virus transiently stimu-
lated naive B-cell proliferation in the presence of the TLR7 ligand R837, while addition of the TLR7 antagonist
IRS 661 impaired cell growth induced by untreated EBV. Interferon regulatory factor 5 (IRF-5) is a down-
stream mediator of TLR7 signaling. IRF-5 was induced following EBV infection, and IRF-5 was expressed in
B-cell lines with type III latency. Expression of IRF-5 in this setting is surprising since IRF-5 has tumor
suppressor and antiviral properties. B-cell proliferation assays provided evidence that EBV modulates TLR7
signaling responses. Examination of IRF-5 transcripts identified a novel splice variant, V12, that was induced
by EBV infection, was constitutively nuclear, and acted as a dominant negative form in IRF-5 reporter assays.
IRF-4 negatively regulates IRF-5 activation, and IRF-4 was also present in type III latently infected cells. EBV
therefore initially uses TLR7 signaling to enhance B-cell proliferation and subsequently modifies the pathway
to regulate IRF-5 activity.
The innate immune system is the cell’s first defense against
viruses. Detection of microbial pathogens is mediated through
recognition of pathogen-associated molecular patterns by cel-
lular pattern recognition receptors that include cytosolic mol-
ecules such as RIG-I, which senses single-stranded RNA from
negative-strand viruses and has also been reported to recog-
nize the polymerase III EBERs synthesized by Epstein-Barr
virus (EBV) (57) and Toll-like receptors (TLRs) (12, 24, 32).
Herpes simplex virus (HSV), varicella-zoster virus, and the
human and mouse cytomegaloviruses (CMVs) are recognized
by the plasma membrane TLR2 receptor (19). In the case of
human CMV, the recognition was mediated by glycoproteins B
and H (11). Protection against murine CMV and HSV type 2
infections is also mediated by endosomal TLR9 (46, 64). The
responses induced by virus recognition of TLRs are dependent
on the cell type, as well as whether or not the virus has mech-
anisms to counter TLR signaling. For example, TLR signaling
in plasmacytoid dendritic cells elicits the secretion of large
amounts of type I interferons, while peritoneal macrophages
secrete predominantly inflammatory cytokines (19).
Relatively little is known about the interaction of EBV with
the TLR pathway or about the mechanisms of EBV evasion of
the innate immune response. More than a decade ago, it was
observed that B-cell lines expressing the full complement of
latency genes (type III latency) were resistant to the effects of
interferon treatment and this resistance required the presence
of intact EBNA2 and EBNA-LP genes (2, 29). In addition to
the recent description of an interaction with RIG-I, the
EBERs have been reported to inhibit interferon-stimulated
gene activity by binding to PKR (double-stranded RNA-de-
pendent protein kinase) and inhibiting its activation (50).
LMP1 interrupts the interferon pathway by preventing TYK2
and STAT2 phosphorylation after interferon treatment (20),
but enigmatically, LMP1 has also been reported to establish an
antiviral state in cells by promoting the expression of interferon-
stimulated genes such as those for oligoadenylate synthetase
and ISG15 (74). Conditional expression of EBNA2 has also
been found to induce the expression of interferon-stimulated
genes (30).
While TLRs serve as sensors of pathogen invasion, the ac-
tivation of pathways such as the MAPK, PI3K, and NF-B
pathways (1) by TLR signaling can be highjacked by viruses to
activate their own gene expression and establish infection. The
naive B cell is the target of EBV infection in vivo (28, 67).
Human B cells express cell surface TLR1, -2, and -6 and
endosomal TLR7, -9, and -10. Two studies found TLR6, -7, -9,
and -10 to be more highly expressed on memory B cells than on
naive B cells (8, 26). Activation of B cells is stimulated by the
binding of antigen to the B-cell receptor and by survival signals
produced by CD40 signaling. Stimulation of the TLR7 and
TLR9 pathways provides additional signals that drive B cells to
proliferate. Unmethylated, CpG-rich bacterial DNA induces
splenic B-cell proliferation through TLR9 (1, 38). Synthetic
ligands of TLR7, R837, and R848, which are members of the
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imidazoquinoline family, also activate B cells and induce their
proliferation (68). R848-induced signaling was found to be
similar to that induced by CD40 ligand in that NF-B and
c-Jun were both activated (9, 10). The effect of TLR signaling
on B-cell activation is also apparent in situations where chro-
matin-immunoglobulin complexes inappropriately activate B
cells through synergistic BCR and TLR stimulation and lead to
autoimmune disease (40).
EBV infection of B cells induces B-cell activation and pro-
liferation. The EBV latency membrane protein LMP1 is es-
sential for B-cell immortalization in vitro (33). LMP1 functions
as a constitutively active, ligand-independent tumor necrosis
factor receptor to activate the NF-B, MAPK, PI3K, and
JAK3/STAT pathways (16, 18, 21, 27, 45) and provide signals
equivalent to those induced by CD40 ligand (35, 69). The
LMP2 latency membrane protein is not essential for in vitro
B-cell immortalization (60) but provides important in vivo sur-
vival signals that mimic those arising from B-cell receptor
activation (55, 63). The recent recognition that TLR signaling
may serve as a third signal for optimal B-cell activation, along
with antigen binding to the B-cell receptor and CD40 stimu-
lation (56), led us to investigate interactions between the EBV
and TLR pathways. We found upregulation of interferon stim-
ulated genes driven by EBV contact with the B cell. Among the
upregulated cell genes were TLR7 and MyD88 (myeloid dif-
ferentiation factor 88), a key participant in TLR signal trans-
duction. EBV infection also upregulated the downstream
TLR7 effector IRF-5. Follow-up experiments provided evi-
dence for a contribution of TLR7 signaling to the initial stages
of EBV-induced B-cell proliferation and for subsequent virus-
induced downmodulation of the IRF-5 arm of the pathway.
EBV is thus able to take advantage of the proproliferative
effects of TLR signaling while limiting IRF-5-mediated nega-
tive effects that would compromise the ability to establish a
persistent EBV infection.
MATERIALS AND METHODS
Cell lines and B-cell isolation. The Akata-4E3, Akata-BX1, Akata, Daudi,
Mutu I, Mutu III, Rael, Ramos, EREB2-5 (in 1 M -estradiol), Snu719 gastric
carcinoma (34), LCL (Akata immortalized primary B cells; gift from C. Farrell,
Johns Hopkins University), P3HR-1, BC-2, and 1852 (containing LMP-1 under
the control of a tetracycline-responsive promoter) (35) cell lines were maintained
in RPMI medium supplemented with 10% fetal bovine serum and antibiotics
(penicillin and streptomycin). The HeLa and 293 adherent cell lines were main-
tained in Dulbecco modified Eagle medium supplemented with 10% fetal calf
serum. Primary B cells were selected from peripheral blood mononuclear cells
(PBMC) after infection with the MACS CD19 positive-selection kit (Miltenyi
Biotec). Naive B cells were isolated from PBMC prior to infection by negative
selection (Cambrex) with MACS naive B-cell isolation kit II. After separation,
cell purity was checked by fluorescence-activated cell sorter (FACS) with a
FACScalibur (Becton Dickinson) and phycoerythrin (PE)-CD27 and fluorescein
isothiocyanate (FITC)-CD19 antibodies (eBioscience).
Reverse transcriptase PCR (RT-PCR). RNA was extracted from cell lines or
EBV-infected B cells with the RNeasy kit (QIAGEN) and DNase treated with
the DNA-free kit (Ambion) according to the manufacturers’ instructions. Re-
verse transcription was carried out with avian myeloblastosis virus reverse trans-
criptase (Promega) by following the manufacturer’s protocol. The amount of
cDNA added to each PCR mixture was normalized relative to the levels of
TATA binding protein (TBP). PCRs were performed with PCR Master Mix
(Promega) or Platinum PCR Master Mix (Invitrogen). Real-time reactions were
performed with SYBR green master mix (AB). All primers were checked for
specificity with BLAST. RT-negative samples were used to check for DNA
contamination. Real-time products were analyzed by a melting curve or agarose
gel electrophoresis to confirm product size and the presence of a unique band.
PCR products were run on 2% agarose gels and visualized by ethidium bromide
staining. The primers used were for TBP (sense, 5 CACGAACCACCGGCAC
TGATT; antisense, 5 TTTTCTTGCTGCCAGTCTGGAC), IRF-5 (LGH 5091
sense, 5 AGGAAGAGCTGCAGAGGATG; LGH 5176 antisense, 5 CCTCC
AGCTGGCTGTAGAAG), V12 IRF-5 (LGH 6228 sense, 5 GAAGAGGAAG
AGAGGATGTCA; LGH 5176 antisense, see above), IRF-3 (sense, 5 CCAAA
GCCACGGATCCTG; antisense, 5 CTGGGTATCAGAAGTACTGC), IRF-3A
(sense, 5 GTTGGAGCTGCAGGGTTACG; antisense, same as IRF-3), TLR7
(sense, 5 TGTTTCCAATGTGGACACTGAA; antisense, 5 TGTTCGTGGGAA
TACCTCCAG), TLR9 (sense, 5 CTGCCACATGACCATCGAG; antisense, 5
GGACAGGGATATGAGGGATTTGG), TLR10 (sense, 5GGTTATTATGCTA
GTTCTGGGGTTGG; antisense, 5GTGCATTGACCTAGCATCCTGAGATA),
EBNA2 (quantitative PCR) (sense, 5 CATAGAAGAAGAAGAGGATGAAGA;
antisense, 5 GTAGGGATTCGAGGGAATTACTGA) (28), EBNA2 (semiquan-
titative RT-PCR) (sense, 5 AGAGGAGGTGGTAAGCGGTTC 3; antisense, 5
TGACGGGTTTCCAAGACTATCC 3) ISG15 (sense, 5 GAGAGGCAGCGA
ACTCATCT; antisense, 5 GCCAATCTTCTGGGTGATCT), PKR (sense, 5
ACGCTTTGGGGCTAATTCTT; antisense 5 TTCTCTGGGCTTTTCTTC
CA), IFIT4 (sense, 5 CGGAACAGCAGAGACACAGA; antisense, 5 TGCT
TGGTCAGCATGTTCTT), MXI (sense, 5 GTGCATTGCAGAAGGTCAGA;
antisense, 5 TTCAGGAGCCAGCTGTAGGT), RANTES (sense, 5 CGCTG
TCATCCTCATTGCTA; antisense, 5 GAGCACTTGCCACTGGTGTA),
MYD88 (sense, 5 AGAGCAAGGAATGTGACTTCCAGA; antisense, 5 GT
GTAGTCGCAGACAGTGATGAACC), tumor necrosis factor alpha (sense, 5
CCCCTCAGCTTGAGGGTTTG; antisense, 5 TGCTGCACTTTGGAGTGA
TC), OAS2 (sense, 5 ACAGCTGAAAGCCTTTTGGA; antisense, 5 AAGTT
TCGCTGCAGGACTGT), STAT1 (sense, 5 CCGTTTTCATGACCTCCTGT;
antisense, 5 TGAATATTCCCCGACTGAGC), OASL (sense, 5 TTTCTGAG
GCAGGAGCATTAG; antisense, 5 CTCCTGGAAGCTGTGGAAAC), and
IFITM1 (sense, 5 ATGGTAGACTGTCACAGAGC; antisense, 5 CTGGTCC
CTGTTCAACACCC).
5 Rapid amplification of cDNA ends (RACE). Total RNA was extracted from
Mutu III cells with the RNeasy kit (QIAGEN). RNA was DNase treated with
DNA-free (Ambion). After phenol-chloroform extraction, an adaptor was added
to the 5 end of the mRNA in three steps with the First Choice RNA ligase-
mediated (RLM)-RACE kit (Ambion) by following the manufacturer’s protocol.
Reverse transcription was carried out on the resulting RNA with an antisense
IRF-5 primer (5 CAGCTGGTTCGTGTAGAAGCGCTG 3) and Thermo-
script RT (Invitrogen) as recommended by the manufacturer. The first step of
the nested PCR was carried out on the cDNA with a sense outer primer com-
plementary to the adaptor and antisense IRF-5-specific outer primer LGH 5176
(5 CCTCCAGCTGGCTGTAGAAG 3). The second step of the nested PCR
was carried out with a sense inner primer complementary to the adaptor and
antisense V12 IRF-5-specific primer LGH 6816 (5 GCGGCCACTTGACATC
CTCTCTTCCTCTTCTTC 3). Platinum Taq DNA polymerase High Fidelity
(Invitrogen) was used in all of the PCRs, and DNA product bands were extracted
from an agarose gel with a Minelute kit (QIAGEN). PCR products were cloned
into pCR2.1 with the Topo TA cloning kit (Invitrogen) and sequenced by the
Johns Hopkins Sequencing Core.
EBV infection. Cells were infected with green fluorescent protein (GFP)-BX1
virus (42) in a small volume, after which they were diluted 5- to 10-fold into
medium. Cells were harvested at time points following dilution. Virus stocks
were divided into two with one-half being treated with Trioxsalen (150 M;
Calbiochem) for 10 to 15 min at room temperature. This stock was transferred
to a FEP bag (Vuelife) and UV irradiated at 4 J/cm2 with a UV irradiator
(Illuminator; Cerus). Unbound Trioxsalen was removed by washing twice with 40
volumes of RPMI medium with a Centricon-Plus 70 filter. Both irradiated and
untreated virus samples were washed. The virus was then filtered with a 45-m-
pore-size filter and stored at 4°C.
Reporter assays. We seeded 1  105 293 adherent cells per well in a six-well
plate and transfected them with calcium phosphate the next day. IFNA1 pro-
moter luciferase reporter (1.0 g per well; gift from Y. Yuan, University of
Pennsylvania) was transfected with 0.3 g of a Renilla luciferase construct which
was used to normalize the transfection efficiency. IRF-5 constructs were cotrans-
fected starting with 0.5 g/well, and SG5 plasmid was used to equalize the
amount of DNA transfected. Cells were harvested 24 h after transfection with
300 l of Glo lysis buffer (Promega) per well. Luciferase assays were performed
with 20 l of lysate and a Lumat (Berthoid) luminometer. Results shown are the
average of two independent assays each done in duplicate.
B-cell proliferation assays. Naive B cells were infected immediately after
separation from PBMC in the presence or absence of R837 (2 to 10 g/ml;
Invivogen). After 3 h, the cell culture was diluted and aliquoted into a 96-well
plate for a final concentration of 2.64  104 cells/300 l/well. R837 or inhibitor
VOL. 81, 2007 EBV INTERACTION WITH THE TLR7 PATHWAY 9749
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treatments were supplemented every 2 to 3 days as noted in the figure legends.
Synthetic oligonucleotides with phosphorothioate backbones IRS 661 (5-TGC
TTGCAAGCTTGAAGCA-3) and a control oligonucleotide (5-TCCTGCAG
GTTAAGT-3) were described by Barrat et al. (6) and synthesized by Integrated
DNA Technologies Inc. The B-cell proliferation in each well was measured in
duplicate with the Cell Titer Glo assay (Promega). Each sample type was set up
in duplicate for every time point. The results shown are representative of two
experiments. Error bars represent standard deviations.
Isoform analysis. IRF-5 variants were identified from a pool of PCR products
resulting from two consecutive rounds of PCR performed on cDNA made from
RNA harvested from EBV-infected primary B cells with primers LGH 5474
(sense, 5 TTATTCTGCATCCCCTGGAG 3) and LGH 5176 (antisense, see
above). PCR products were TA cloned into pCR2.1 (Invitrogen) and sequenced.
Western blotting. Endogenous IRF-5 was analyzed in cells that were washed in
phosphate-buffered saline and lysed in lysis buffer (50 mM Tris [pH 7.6], 50 mM
NaCl, 0.5 mM EDTA, 0.2% NP-40, and 1% glycerol with protease inhibitors) at
a concentration of 1  107 cells per ml. Cells were lysed at 4°C for 15 min,
sonicated, and then centrifuged for 30 min at top speed at 4°C. -Tubulin was
used to normalize the amount of whole-cell lysate loaded onto a 12% sodium
dodecyl sulfate-polyacrylamide electrophoresis gel and transferred to a Trans-
blot nitrocellulose membrane (Bio-Rad). The membrane was probed with anti-
bodies to IRF-5 (Protein Tech Group), IRF-3 (Santa Cruz), -tubulin (Sigma),
IRF-4 (Cell Signaling), and LMP-1 (DAKO). The secondary antibodies used
were horseradish peroxidase-conjugated anti-rabbit and anti-mouse antibodies
(Amersham Biosciences). Protein bands were visualized with the ECL system
(Amersham Biosciences). Membranes were stripped for reprobing with Restore
Western blot stripping buffer (Pierce). IRF-5 variants were in vitro translated
with the Quik Coupled Transcription/Translation System (Promega). Samples
were subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis, and after being blocked in 5% milk–phosphate-buffered saline–Tween 20, the
membrane was probed with an anti-hemagglutinin (HA) antibody (rabbit; Santa
Cruz) and a horseradish peroxidase-conjugated anti-rabbit secondary antibody
(Amersham Biosciences).
Plasmids. HA–IRF-5 (variant 3) was constructed by ligating a PCR product
containing the IRF-5 N-terminal 300 bp amplified from an IRF-5 cDNA (Im-
ageClone) with a cDNA obtained from a B-cell Gal4ACT library (Clontech) into
an SG5 vector (Invitrogen) modified to contain a Gateway cassette and an HA
tag. Other variants were cloned by digestion of PCR products generated with
IRF-5 primers LGH5474 and LGH5176 with SmaI, which has recognition sites
flanking the IRF-5 variable region. The individual variable regions were then
inserted into HA–IRF-5 between the SmaI sites. Phosphomimetic IRF-5, variant
3 (PV3), was made in the Gateway Entry vector with the Quick Change kit
(Stratagene) to convert IRF-5 serines 425, 427, and 430 into glutamic acid. The
phosphomimetic IRF-5 protein was then HA tagged with the Gateway system.
Immunofluorescence. HeLa cells seeded at 1.2 104 per well were transfected
with 0.5 g of each DNA by calcium phosphate precipitation. Two days after
transfection, cells were fixed in methanol and probed with an anti-HA rabbit
primary antibody (Upstate) and a rhodamine-conjugated goat anti-rabbit sec-
ondary antibody (Jackson). Nuclei were stained with 4,6-diamidino-2-phenylin-
dole (DAPI) in Vectashield mounting solution (Vector Laboratories), and
cells were photographed with a fluorescence microscope and Image-Pro Plus
software.
RESULTS
UV-inactivated EBV induces the expression of interferon-
responsive genes in naive B cells. Virus infection induces a
cellular immune response. Studies with CMV have found
that virus binding and entry are sufficient to induce inter-
feron and proinflammatory cytokine responses (59). To
evaluate the consequences of EBV infection in the absence
of viral gene expression, virus prepared from lytically in-
duced Akata-BX1 cells was aliquoted and half of the stock
was subjected to UV inactivation. To validate the effective-
ness of the UV treatment, EBV-negative 4E3 B cells were
infected with UV-treated or untreated virus and 24 h after
infection the cells were analyzed by FACS for GFP ex-
pressed from the recombinant BX1 virus. A GFP-positive
cell population was observed after infection with untreated
EBV, but the GFP signal in the cells infected with UV-
treated virus did not differ from that seen in mock-infected
4E3 cells (Fig. 1A). Expression of the EBV EBNA2 gene
was also examined by real-time RT-PCR (Fig. 1B). EBNA2
transcripts appeared 5 h after infection of 4E3 cells with
untreated virus, and expression continued for the 5-day pe-
riod of the experiment. No EBNA2 transcripts were de-
tected in 4E3 cells infected with UV-treated virus. The UV
treatment was therefore effective in preventing expression
from the EBV genome.
The predominant target for EBV infection in vivo is believed
to be the naive B cell (28, 67). Naive B cells were separated
from PBMC by negative selection with the MACS naive B-cell
isolation kit. FACS analyses of PBMC and the naive B-cell frac-
tion stained with PE-labeled anti-CD27 (memory B-cell marker)
and FITC-labeled anti-CD19 (pan-B-cell marker) antibodies
was used to verify successful enrichment of the naive B-cell
population (Fig. 1C). Naive B cells were then infected with
UV-inactivated or untreated virus, and 5 h later RNA was
isolated and the expression of a panel of interferon-stimulated
genes was examined by real-time RT-PCR with the assays
being performed in triplicate. Eleven of 12 tested cell genes
were induced by both UV-inactivated and untreated virus. The
exception was the proinflammatory cytokine tumor necrosis
factor alpha, which did not respond to either infection at this
early time point (Fig. 1D). The data indicate that contact
between EBV and the cell in the absence of EBV gene expres-
sion is sufficient to induce the cell to upregulate interferon-
stimulated genes. Interestingly, two of the induced genes,
TLR7 and MyD88, are participants in the TLR signaling
pathway.
TLR7 is specifically induced by EBV contact with B cells.
Naive B cells express detectable amounts of TLR1, TLR2,
TLR6, TLR7, TLR9, and TLR10, although expression is re-
ported to be low compared to that seen in memory B cells (8,
48). Naive B cells were infected with UV-inactivated or un-
treated EBV, and TLR expression was examined by real-time
RT-PCR at 5 h and 11 h after virus addition. TLR7 was the
only one of these TLRs that was induced by EBV. UV-inacti-
vated (open bars) and untreated virus (filled bars) stimulated
TLR7 expression two- to threefold at 5 h and six- to sevenfold
at 11 h (Fig. 2A). In contrast, TLR9 and TLR10 expression
decreased in comparison to that in uninfected cells (Fig. 2A)
and TLR1 and TLR6 expression showed no significant change
(data not shown). Monitoring of EBNA2 expression in the
same infections confirmed that EBNA2 was expressed at 5 and
11 h after infection with untreated virus and was not expressed
in cells incubated with UV-inactivated virus (Fig. 2B).
EBV interaction with the TLR7 pathway enhances B-cell
proliferation. Two approaches were taken to evaluate
whether TLR7 signaling contributed to the early stages of
EBV-induced B-cell proliferation. Firstly, the growth of na-
ive B cells was compared before and after induction of
TLR7 by UV-inactivated virus and in the presence or ab-
sence of the TLR7 ligand R837. Cells were harvested after
3 days in culture, and the cell number was assayed with
Cell-Titer Glo (Fig. 3A). Addition of R837 (2 g/ml) to
naive B cells reduced cell numbers twofold. Addition of
UV-inactivated EBV produced a threefold growth stimula-
tion. However, addition of inactivated virus plus R837 re-
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sulted in an augmented 17-fold increase in growth. In a
complementary approach, naive B cells were infected with
untreated EBV in the presence or absence of the TLR7
inhibitory oligonucleotide IRS 661 (Fig. 3B). EBV-induced
proliferation was decreased in the presence of IRS 661
(filled triangles). These experiments indicate that the EBV-
induced TLR7 is functional and that stimulation of TLR7
signaling enhances EBV-driven growth of naive B cells.
Expression of TLR7 and its downstream effector IRF-5 in
B-cell lines. To evaluate whether TLR7 signaling might play a
role at later times after EBV infection, TLR expression was
compared in an EBV-positive LCL cell line with type III la-
tency versus EBV-negative 4E3 cells. The two cell lines showed
equal expression of TLR10, but TLR7 was overexpressed and
TLR9 was underexpressed in the LCL cell line relative to 4E3
cells (Fig. 4A). 4E3 cells were then infected with EBV, and the
expression of TLR7 and its downstream effector IRF-5 was
examined by real-time RT-PCR. EBV infection of 4E3 cells
induced TLR7 and IRF-5 expression (Fig. 4B and D). (The
FIG. 1. UV-inactivated EBV induces ISG expression in naive B
cells. (A, B) Confirmation of EBV inactivation. 4E3 cells were infected
with EBV-BXI from untreated or UV-inactivated stocks. (A) Cells
were harvested at 24 h and analyzed by FACS. GFP expression levels
were compared in mock-infected (top), UV-inactivated-EBV-infected
(middle), and untreated-EBV-infected (lower) cells. (B) RNA was
harvested from infected 4E3 cells, and RT-PCR was performed to
detect transcript levels of EBNA2. (C) Naive B cells were separated
from PBMC by negative selection. PBMC and the naive B-cell frac-
tions were stained with PE-labeled anti-CD27 antibody (memory B-
cell marker) and FITC-labeled anti-CD19 antibody (pan-B-cell
marker) and analyzed by FACS. (D) Interferon-stimulated genes are
induced in naive B cells by UV-inactivated and untreated EBV infec-
tion. RNA isolated from naive B cells 5 h after infection with UV-
inactivated or untreated EBV was amplified by real-time PCR. Values
are relative to those of uninfected naive B cells. Real-time assays were
performed in triplicate, and results are representative of at least two
experiments.
FIG. 2. EBV induces TLR7. EBV infection induces TLR7 but re-
presses TLR9 and -10 expression in naive B cells. Cells were infected
with EBV (filled bars) or UV-inactivated EBV (open bars), and RNA
was isolated at the indicated times after infection. (A) TLR expression.
(B) EBV EBNA2 expression. RNA was quantified by real-time RT-
PCR. The results are representative of two independent experiments
performed in triplicate.
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IRF-5 RT-PCR products reflect the presence of alternatively
spliced IRF-5 variants.) The time courses of induction of TLR7
and IRF-5 were similar and were delayed relative to EBNA2
expression (Fig. 4C) and to the time course of TLR7 induction
in primary B cells.
IRF-5 protein expression was also examined in EBV-posi-
tive cell lines. Western blotting with anti-IRF-5 antibody re-
vealed strong expression of IRF-5 proteins in the type III
latently infected B-cell lines LCL, Mutu III, and EREB2-5
(Fig. 4E). The detection of multiple protein bands may reflect
expression from differentially spliced IRF-5 transcripts. IRF-5
protein was either not present or barely detectable in the type
I Burkitt’s lymphoma cell line Mutu I, which is the parent line
of Mutu III; in the EBV-negative Burkitt’s lymphoma cell lines
4E3 and Ramos; or in P3HR-1, in which the gene for EBNA2
is deleted. -Tubulin was used as a loading control for the
Western blot analysis.
EBV gene expression modifies TLR7 signaling. The expres-
sion of IRF-5 protein in type III latently infected cell lines was
surprising given that IRF-5 has been described as having tumor
suppressor and proapoptotic activities (4, 15). It seemed pos-
sible that EBV might be modulating the IRF-5 arm of the
TLR7 response in such a way as to minimize negative out-
comes. To evaluate this scenario, the effects of overstimulation
of the TLR7 pathway with increased doses of the TLR7 ligand
R837 were investigated. With EBV-infected naive B cells, we
found that treatment with a 10-fold dose (20 g/ml) of R837 at
the time of EBV infection was growth inhibitory and prevented
EBV-induced B-cell proliferation (Fig. 5, filled squares versus
triangles). However, when the naive B cells were infected with
EBV and left for 2 days to allow time for expression of EBV
latency III genes prior to the addition of 20 g/ml R837, this
growth inhibition was completely overcome (Fig. 5, circles).
This result suggests that the functioning of the TLR7 pathway
is modified subsequent to the initial infection.
EBV induction of a novel negative regulatory IRF-5 splice
variant, V12. IRF-5 is expressed as multiple splice variants, and
expression of particular splice variants has recently been linked
to the development of systemic lupus erythematosus (22).
IRF-5 splice variant expression in EBV-infected primary B
cells was investigated by amplifying IRF-5 transcripts with
primers from either exon 2 or exon 4/5 to exon 7. The PCR
products obtained were cloned and sequenced. No evidence
was found for the splice variant associated with systemic lupus
erythematosus, but a previously undescribed splice variant,
V12, was identified. Two forms of V12 were isolated that
differed by 30 bp in the exon 6 variable region. A comparison
of the predicted amino acid sequence of the common region of
V12 with the previously described V1 and V3 IRF-5 variants
(Fig. 6A) shows that V12 would encode a DNA binding domain
in the absence of an activation domain and hence could function
as a negative modulator of IRF-5 transcriptional activity.
It has been suggested that splice variant expression is de-
pendent on promoter usage (47). Four potential promoter
regions have been described for IRF-5. Two of these were
found to have activity when cloned into reporter vectors (47),
and another was identified as the source of transcripts in sys-
temic lupus erythematosus patients (22). To determine the
structure of the V12 IRF-5 transcripts in Mutu III cells, 5
RLM RACE was performed with a 3 primer located across
the exon 4-to-6 splice site. The RLM RACE procedure spe-
cifically amplifies 5-capped mRNAs. Sequencing of the cloned
cDNA products identified V12 transcripts that were derived
almost equally from the distal and proximal IRF-5 promoters
(Fig. 6B). Interestingly, the five sequenced cDNAs initiating
from the proximal promoter all had the identical 5 start point
at 1,408 bp from the IRF-5 ATG initiator codon, while the
three sequenced cDNAs arising from the distal promoter ini-
tiated at two different positions within a 314-bp region. The 5
termini were located 4,366 and 4,052 bp from the IRF-5 ATG.
This type of stuttered 5 initiation is typical of RNAs arising
from TATA-less promoters. From the RACE analysis, we ob-
tained promoter usage and coding sequence information for
the V12 variant.
The PCR primers used to examine IRF-5 mRNA induction
in Fig. 4 would not have detected the V12 splice variant.
V12-specific primers were designed, and V12 expression was
examined following EBV infection of Ramos cells (Fig. 6C).
EBV-negative Ramos cells expressed low levels of the V12
transcript prior to infection and V12 was upregulated between
6 and 24 h after infection. Since the V12 transcript was up-
regulated by EBV infection, expression of V12 was also exam-
ined in established B-cell lines. The Mutu III and LCL cell
lines that express IRF-5 mRNA and protein also expressed the
FIG. 3. EBV-mediated stimulation of TLR7 enhances B-cell pro-
liferation. (A) Naive B cells were incubated with UV-inactivated virus
in the presence or absence of R837 (2 g/ml) for 3 days. (B) Naive B
cells were infected with BXI virus in the presence of a control oligo-
nucleotide or IRS 661 (TLR7 inhibitory oligonucleotide) at 2.8 M.
Cells were treated at days 0, 3, and 5. Cell growth was quantitated in
quadruplicate with Cell Titer Glo (Promega). Results are representa-
tive of two independent experiments. The standard deviation is shown.
RLU, relative light units.
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V12 mRNA (Fig. 6D and E, lanes 2 and 5), with Mutu III
expressing both V12 forms. The available IRF-5 antibody did
not recognize the V12 protein, and so endogenous V12 protein
expression could not be examined.
To verify that V12 encodes a truncated IRF-5 protein, in vitro
transcription-translation of the HA-tagged V12 cDNA was per-
formed. A smaller 22-kDa polypeptide was generated by the V12
cDNA compared to the approximately 60- to 63-kDa polypep-
tides generated by HA-tagged V3 and V5 cDNAs (Fig. 7A). To
examine whether the V12-encoded protein had the properties of
a negative modulator of IRF-5 transactivation, V12 IRF-5 was
further characterized. V12 lacks the nuclear export signal en-
coded in exon 5 (44), and as seen in transfected cells, V12 was
constitutively nuclear (Fig. 7B). This contrasts with the constitu-
tively cytoplasmic localization of the V3 and V5 variants but is
similar to the nuclear localization of a modified constitutively
activated phosphomimetic V3 (PV3, Fig. 7B). In this phosphomi-
metic V3 version, the serine residues at positions 425, 427, and
430 were mutated to glutamic acid. A similar phosphomimetic V1
IRF-5 version has been described in which these residues were
changed to aspartic acid (44).
Finally, the functional activity of V12 was compared with
that of V3 and PV3 in a reporter assay with the IFNA1 pro-
moter which is known to be IRF-5 responsive (5, 43). V3
activated expression of the promoter-luciferase reporter 20-
fold, and constitutively activated PV3 gave a 340-fold activa-
tion (Fig. 7C). V12 did not affect reporter expression when
transfected alone, but cotransfection of V12 with PV3 resulted
in dose-dependent downregulation of PV3 activation (Fig. 7C).
Thus, induction of V12 upon EBV infection and V12 expres-
FIG. 4. Expression of TLR7 and IRF-5 is associated with EBV primary infection, as well as type III latency. (A) TLR7 is upregulated in type III LCLs.
Comparison of TLR7, TLR9, and TLR10 expression in the type III latently infected LCL cell line versus the EBV-negative 4E3 cell line. RNAs were
quantified by real-time RT-PCR and gene-specific primers. The results are an average of two independent experiments performed in triplicate. (B, C)
Induction of TLR7 after infection of EBV-negative 4E3 B cells. TLR7 (B) and EBV EBNA2 (C) RNAs were quantified by real-time RT-PCR. RNA
was isolated at the indicated times after infection. The results are an average of two independent experiments performed in triplicate. (D) EBV induces
IRF-5 transcripts. Shown are ethidium bromide-stained gels of electrophoretically separated RT-PCR products amplified from EBV-negative 4E3 B cells
before (0 h) and at the indicated times after infection with Akata-BX1 virus. Primers were specific for IRF-5 (upper), EBV EBNA2 (middle), and TBP,
which served as a loading control (lower). The results are representative of two independent experiments. (E) IRF-5 is expressed in type III latently
infected cell lines. Western blot probed with anti-IRF-5 antibody comparing IRF-5 protein expression in type III latently infected cell lines (LCL, Mutu
III, and EREB2-5), the EBV-positive EBNA2 deletion-containing cell line P3HR-1, a type I latently infected cell line (Mutu I), and EBV-negative B-cell
lines (4E3 and Ramos). Equality of protein loading was determined by probing the membrane with anti--tubulin antibody.
FIG. 5. EBV ameliorates negative growth effects following over-
stimulation of TLR7. Naive primary B cells were infected with EBV in
medium without or with R837 (20 g/ml) added initially at the time of
infection (day 0) or 2 days postinfection (day 2) and subsequently
supplemented on days 2 and 5. Cell proliferation was measured in
quadruplicate with the Cell Titer Glo assay. The data shown are rep-
resentative of two independent assays. The standard deviation is
shown. RLU, relative light units.
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sion in type III latently EBV-infected cells could modulate
IRF-5 functional activity in these cells.
IRF-4, a negative regulator of IRF-5 activity, is upregulated
in type III latency. IRF-4 is an IRF family member that neg-
atively modulates TLR-mediated IRF-5 activation by compet-
ing with IRF-5 for interaction with MyD88 (51). IRF-4 was
among the cellular genes found by gene array analysis to be
upregulated in EBV type III latency (13) and upregulated by
EBNA2 in EREB2-5 cells (61), but IRF-4 expression in EBV-
infected cells was not further characterized. Expression of
IRF-4 in IRF-5-expressing and -nonexpressing B-cell lines was
therefore examined by Western blotting (Fig. 8A). IRF-4 was
strongly expressed in the same type III cell lines, LCL,
EREB2-5, and Mutu III, that showed high-level expression
of IRF-5 and was not detected in the non-IRF-5-expressing
P3HR-1 and Mutu I cell lines. In contrast to IRF-5 and
IRF-4, IRF-3 was uniformly expressed in the cell lines tested
(Fig. 8A).
To demonstrate that EBV latency gene expression induced
IRF-4, we monitored the expression of IRF-4 in type III
EREB2-5 cells grown in the presence or absence of estrogen.
EREB2-5 cells contain estrogen-regulated EBNA2, and in the
absence of estrogen, EBNA2 is cytoplasmic and transcription-
ally inactive (34). Removal of estrogen therefore leads to loss
of expression of all EBNA2-regulated latency genes, including
LMP-1. After estrogen withdrawal, IRF-4 protein expression
was downregulated with the same kinetics as LMP1 protein
expression and only trace amounts of IRF-4 were expressed in
the absence of LMP1 (Fig. 8B). IRF-4 expression also followed
LMP1 expression upon resupplementation of the medium with
estrogen, with the expression of both proteins rebounding rap-
idly (Fig. 8B, 4/1 days). This result confirms the induction
of IRF-4 by EBNA2 or EBNA2-regulated EBV genes ex-
pressed in type III latently infected cells. The reduced levels
of IRF-4 seen in EBNA2 deletion-containing P3HR-1 cells
(Fig. 8A) may consequently reflect the loss of EBNA2 in this
cell line.
LMP1 is one of the latency genes that are regulated by
EBNA2. To determine whether LMP1 contributed to IRF-4
induction, the 1852 cell line was used. This cell line was gen-
erated by infecting primary B cells with a recombinant mini-
EBV in which LMP1 is expressed from a tetracycline-regulated
promoter (35). After 3 days of washing to remove tetracycline
from the culture medium, no LMP1 was detected (Fig. 8C,
time zero). Within 8 h of addition of tetracycline to the me-
dium, LMP1 protein expression increased and expression con-
tinued throughout the 3-day period of the experiment. IRF-4
protein expression was minimal at time zero, but IRF-4 ap-
peared at 8 h and continued to be expressed at subsequent
time points. LMP1 therefore contributes to the induction of
IRF-4. Thus, in addition to modulation of IRF-5 DNA binding,
IRF-5 activation in response to TLR signaling would be neg-
atively modulated in type III latent infection.
DISCUSSION
The changes in B-cell growth induced by EBV infection are
thought to mimic those that occur during the natural process of
B-cell activation and differentiation (67). Two of the key nat-
ural signals for B-cell activation, namely, ligand interactions
with the CD40 receptor and the BCR, are supplied by the
constitutive signaling activity of the EBV LMP1 and LMP2
proteins. We now provide evidence that a third proliferative
FIG. 6. EBV infection induces a novel alternative splice variant of
IRF-5, V12. (A) Exon structure of IRF-5 showing the predicted amino
acid sequence of the variable exon 4 to 6 region of the V1, V3, and V12
cDNAs amplified by RT-PCR from EBV-infected cells. NLS, nuclear
localization signal (3). NES, nuclear export signal (15, 44). DBD, DNA
binding domain. TAD, transactivation domain. (B) Diagram of the
structure of V12 cDNAs amplified by 5 RLM RACE from Mutu III
cells and cloned and sequenced. Shaded box, promoter region. (C to
E) Ethidium bromide-stained, electrophoretically separated RT-PCR
products amplified with primers specific for the V12 variant showing
induction of V12 transcripts after EBV infection of Ramos cells
(C) and expression of V12 transcripts in type III EBV-infected cell
lines (Mutu III and LCL) but not in P3HR-1 or the type I latently
infected B-cell lines (Mutu I, Rael) or gastric carcinoma cells (Snu719)
(E). (D) Generic IRF-5 primers were used to amplify IRF-5 transcripts
in the cell lines used in panel C. Amplification of cellular TBP or the
ubiquitously expressed IRF-3 protein was used as a loading control.
Results are representative of at least two experiments.
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signal provided by TLR signaling (56) is induced by EBV
infection and contributes to the initial B-cell growth response.
Contact between naive B cells and UV-inactivated EBV
upregulated the expression of a number of interferon-respon-
sive genes, including those for TLR7 and MyD88. The virus-
cell interaction provoking the initial interferon response was
not pursued here. However, the described stimulation of TLR2
by HSV, CMV, and varicella-zoster virus glycoproteins sug-
gests that stimulation of TLR2, which is expressed on the
plasma membrane of B cells, is a good candidate. TLR7 was
the only TLR observed to be upregulated and, in contrast
TLR9 expression, was downregulated by contact with un-
treated or UV-inactivated EBV. The repression of TLR9 ini-
tially seems surprising since the HSV and CMV herpesviruses
stimulate TLR9 signaling through their CpG-rich genomes (39,
46, 64) and stable expression of LMP2A in B cells of transgenic
mice moderately upregulated TLR9 expression in a BCR-de-
pendent manner (70). NF-B p65 suppresses TLR9 transcrip-
tion (66). EBV binding to the CD21 cell surface receptor
activates NF-B (62), and a principal function of LMP1 is
NF-B activation. Thus, EBV-induced NF-B activity may be
the source of the TLR9 downregulation. TLR7 and TLR9 also
modulate each other’s activity. TLR7 signaling itself mediates
NF-B activation, creating a negative feedback loop for TLR9
expression, and conversely, TLR9 can physically interact with
TLR7 and inhibit TLR7 function in a dose-dependent manner
(71). MyD88 is an adaptor molecule that, upon TLR stimula-
tion, is recruited to the cytoplasmic tail of all TLRs except
TLR3 (17) and is necessary for the subsequent recruitment of
the tumor necrosis receptor-associated factors TRAF3 and
TRAF6 and the kinases IRAK4 and IRAK1. The upregulation
of TLR7 and its adaptor MyD88, in concert with the down-
regulation of TLR9, would establish conditions suited for
TLR7 pathway activity.
Naive B cells, the target of EBV infection in vivo, have low
TLR expression compared to memory B cells. Proliferation of
naive B cells in response to TLR7 ligand required costimula-
tion with alpha interferon to upregulate TLR7 expression (7).
We also saw no stimulation when naive B cells were treated
with the TLR7 ligand R837 alone, but naive B-cell growth was
stimulated by the combination of R837 and UV-inactivated
EBV, presumably because of the induction of TLR7 and
MyD88 as part of the interferon-stimulated gene response that
followed initial contact between EBV and the B cell. A con-
tribution of TLR7 activity to initial B-cell outgrowth was sup-
ported by the reduced growth observed when the EBV-in-
fected naive B-cell cultures were treated with IRS 661, a
TLR7-specific inhibitory oligonucleotide. While TLR7 expres-
sion is upregulated by EBV contact with the cell in the absence
of viral gene expression, EBV gene expression may be a source
of the single-stranded RNA that normally activates TLR7 sig-
naling.
Two interferon regulatory factors, IRF-5 and IRF-7, are
recruited to MyD88 and activated by TLR7 signaling. IRF-7
was first described in type III latently infected B cells, where it
was identified as a transcription factor that bound and re-
pressed the EBV Qp promoter that serves as an alternative
promoter for driving EBNA1 expression (75). Subsequently,
LMP1 induction and activation of IRF-7 and a positive feed-
back loop of IRF-7 induction of LMP1 were described previ-
FIG. 7. V12 IRF-5 is constitutively nuclear and negatively regulates IRF-5 transactivation. (A) V12 encodes a truncated IRF-5 protein. Western
blot probed with anti-HA antibody comparing the electrophoretic mobility of polyacrylamide gel electrophoresis-separated, HA-tagged, in
vitro-translated V3, V5, and V12 IRF-5 polypeptides. Lane C, control with no added template. NS, nonspecific bands. The values on the right are
molecular sizes in kilodaltons. (B) Immunofluorescence assays comparing the intracellular localization of HA-tagged IRF-5 V3, V5, and V12
proteins and the phosphomimetic V3 protein (pV3) in transfected HeLa cells. Cells were stained with an anti-HA primary antibody and a
rhodamine-labeled secondary antibody. Nuclei were stained with DAPI. (C) Reporter assay in which 293 cells were transfected with an IFNA1
promoter-luciferase reporter in the presence of V3 IRF-5, V12 IRF-5, pV3 IRF-5, or pV3 IRF-5 plus increasing amounts of V12 IRF-5 as
indicated. The data shown are averages from two assays.
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ously (52). IRF-7 activation leads to nuclear translocation and
induction of all of the alpha interferon gene promoters, as well
as the beta interferon gene promoter (25). Despite this activity,
EBV has been able to incorporate IRF-7 into its own biology
in type III latently infected cells. We found that IRF-5 expres-
sion was also induced by EBV infection. Stimulation of TLR7
signaling induces IRF-5 (58), and we noted that IRF-5 induc-
tion after infection of 4E3 B cells coincided temporally with
the time at which TLR7 was upregulated. IRF-5 was initially
identified as a transcription factor expressed as multiple splice
variants that is active on type I interferon promoters (5, 47).
Irf5/ mice have a reduced type I interferon response to HSV
type 1 infection and enhanced viral propagation (72). Alpha
and beta interferon production in response to TLR7 stimula-
tion is also impaired in Irf5/ mice (73). IRF-5 has also been
recognized as a key mediator of cytokine induction after TLR
stimulation and has been proposed to activate cytokine pro-
moters synergistically with NF-B (49, 65). While an initial
induction of cytokines such as interleukin-6 and -12 may be
beneficial for EBV infection, continued interferon production
and IRF-5 activity would be expected to have a negative impact
on EBV-induced B-cell expansion. For example, IRF-5 in-
duces apoptosis in response to DNA damage (72) and BJAB B
cells stably expressing IRF-5 formed fewer and smaller tumors
in mice than did control BJAB cells (4). The continued expres-
sion of IRF-5 in type III cell lines therefore suggested that, as
is the case for IRF-7, EBV must modulate IRF-5 activity to
balance the positive and negative downstream consequences.
Initially to test this hypothesis, EBV infection of naive B cells
was performed in the presence of a 10-fold dose of R837 to
overstimulate the TLR7 pathway. R837 at 20 g/ml completely
blocked B-cell growth when supplied concurrently with virus
infection. However, if EBV latent gene expression was allowed
to initiate prior to the addition of the R837, then there was no
negative effect on growth compared to that of untreated, EBV-
infected B cells, implying that one or more of the EBV latency
gene products was modifying signaling downstream of TLR7.
We explored ways in which IRF-5 activity could be modified
in EBV-infected cells and obtained evidence for two separate
mechanisms. IRF-5 is expressed as multiple splice variants, and
alterations in IRF-5 splicing have been linked to the develop-
ment of systemic lupus erythematosus, suggesting that different
splice variants may differ in their functional properties (22, 23).
An examination of IRF-5 splice variant expression in EBV-
infected cells led to the identification of a novel IRF-5 splice
variant, V12, that was induced by EBV infection and was
expressed in all type III latently infected cells expressing
IRF-5. The V12 sequence encoded a truncated IRF-5 protein
that retained the DNA binding domain but lacked the nuclear
export signal and transactivation domain. In transient expres-
sion assays, V12 was constitutively nuclear and negatively reg-
ulated IRF-5 transactivation of an alpha interferon promoter.
The amount of V12 IRF-5 mRNA in LCL cells was 6.9-fold
less than the sum of the other IRF-5 transcripts, as measured
by quantitative RT-PCR (data not shown). However, the V12
protein is constitutively nuclear and by occupying IRF binding
sites on responsive promoters could attenuate binding by
IRF-5 entering the nucleus in response to signaling. A non-
DNA binding, activation domain-only IRF-5 protein that acted
as a functional negative mutant form in reporter assays has
previously been described (47), as have splice variants of IRF-1
(41), IRF-2 (37), and IRF-3 (31, 36) that have altered func-
tional properties.
We further observed that IRF-4 was consistently expressed
in type III cell lines expressing IRF-5. IRF-4 negatively mod-
ulates IRF-5 activity after TLR stimulation by competing with
IRF-5 for binding to MyD88 (51). EBV genes expressed in
type III latency have been shown to upregulate IRF-4 (13, 61).
Experiments with B-cell lines with conditional expression of
EBNA2 or LMP1 revealed firstly that EBNA2 or EBNA2-
regulated EBV genes were necessary for IRF-4 expression and
secondly that LMP1 was one of the genes responsible for the
induction. The combination of V12 and IRF-4 induction would
provide negative regulation at both the IRF-5 protein activa-
tion and IRF-5 promoter upregulation steps. Further, since
IRF-4 does not compete with IRF-7 binding to MyD88, the
induction of IRF-4 could bias the downstream signal from
TLR7 activation away from an IRF-5 gene expression signa-
ture and toward an IRF-7 signature.
The extent to which IRF-5 is integrated into the regulation
of EBV gene expression remains to be investigated. The only
FIG. 8. EBV induces expression of the IRF-5 negative regulator
IRF-4. (A) Western blot assay comparing the expression of IRF-5 with
that of IRF-4 and IRF-3 in different B-cell lines. Lane 1, 293 cells
transfected with V3 IRF-5. Lanes 2, 4, and 6, type III latently infected
cell lines. Lane 3, EBNA2 deletion-containing P3HR-1 cells. Lane 5,
type I latently infected cell line. -Tubulin served as a control for
protein loading. (B) Western blot assay showing the dependence of
IRF-4 expression on EBV latency gene expression. EREB2-5 cells
were deprived of -estradiol and harvested at the time points noted.
Four days after withdrawal, -estradiol was added back into the me-
dium at 1 M and cells were grown for a further 1 day (4/1). The
membrane was probed with anti-IRF-4 and LMP1 antibodies. -Tu-
bulin was used as a loading control. (C) LMP-1 regulates IRF-4 ex-
pression. 1852, a tetracycline-on LMP-1, type III cell line, was grown in
medium without tetracycline for 5 days, and then tetracycline was
added back to the medium (time zero). A Western blot of the cell
extract was probed with anti-IRF-4 and LMP1 antibodies. -Tubulin
was used as a loading control. The results are representative of two
experiments.
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reports to date have shown that IRF-5 heterodimerization with
IRF-7 negatively affects IRF-7 activation of LMP1 expression
(53) and that IRF-5 is able to downregulate a promoter for the
BamHI-A rightward transcripts (14) that generate EBV-en-
coded microRNAs (54). The induction early after infection of
TLR7 and the TLR7 downstream adaptor MyD88 and effector
IRF-5, along with the effects of the TLR7 ligand R837 and the
TLR7 inhibitor IRS 661 on the proliferation of EBV-infected
naive B cells, indicates that EBV uses TLR7 signaling to pro-
mote the initial phase of B-cell activation and expansion. The
induction of the negative regulators V12 IRF-5 and IRF-4
implies that subsequent modulation of the TLR7 pathway is
necessary for successful establishment of a latent infection.
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